Coverage
-
January 21, 2022
U.S. Circuit Judge Timothy B. Dyk has unsealed his opinion in a Delaware federal court case explaining why he found a Takeda Pharmaceutical Co. Ltd. unit's antibody patent was too broad to meet the enablement requirement, ultimately letting Roche subsidiary Genentech off the hook for infringing with its blockbuster hemophilia drug Hemlibra.
1 other articles on this case.
View all »